Literature DB >> 21130755

Serum MMPs and TIMPs: may be predictors of breast carcinogenesis?

Flora Zagouri1, Theodoros N Sergentanis, Elena Kalogera, Xeni Provatopoulou, Dimosthenis Chrysikos, Eleni Zografos, Garifallia Bletsa, Ioannis Flessas, Christos A Papadimitriou, George C Zografos, Antonia Gounaris.   

Abstract

BACKGROUND: The involvement of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in breast cancer has been documented on palpable lesions. This study aims to assess serum MMP1, MMP-2, TIMP-1, and TIMP-2 in atypical ductal hyperplasia (ADH), lobular neoplasia (LN), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) specifically in non-palpable mammographic breast lesions.
METHODS: On women with benign (n=65), precursor [ADH (n=18) and LN (n=15)], preinvasive [DCIS (n=32)] and invasive [IDC (n=28)] lesions the serum concentrations of MMP-1, MMP-2, TIMP-1, TIMP-2, TPS, and TPA were determined with immunoenzymatic assays. All women had non-palpable mammographic breast lesions of less than 10mm in diameter, as estimated on the mammographic views. Statistical analysis followed.
RESULTS: TIMP-2 serum concentrations were positively associated with the severity of the lesion. On the contrary, MMP-2 levels were marginally negatively associated with severity; as evident, the MMP-2/TIMP-2 ratio significantly decreased along with severity. Regarding TIMP-1, TPS, TPA, and TIMP-1/TIMP-2, no significant associations were demonstrated. MMP-2 and the MMP-2/TIMP-2 ratio were significantly higher in the LN subgroup versus the ADH subgroup.
CONCLUSION: TIMP-2 and MMP-2/TIMP-2 ratio may exhibit meaningful changes along with progression of lesions. Extracellular cell matrix remodeling in ductal and lobular lesions may follow distinct patterns.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21130755     DOI: 10.1016/j.cca.2010.11.037

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  MMP-2 -1306C>T polymorphism in breast cancer: a case-control study in a South European population.

Authors:  Flora Zagouri; Theodoros N Sergentanis; Maria Gazouli; Constantine Dimitrakakis; Alexandra Tsigginou; Irene Papaspyrou; Dimosthenis Chrysikos; Maria Lymperi; George C Zografos; Aris Antsaklis; Meletios-Athanassios Dimopoulos; Christos A Papadimitriou
Journal:  Mol Biol Rep       Date:  2013-05-10       Impact factor: 2.316

2.  TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression.

Authors:  Yixuan Gong; Evita Scott; Rong Lu; Yin Xu; William K Oh; Qin Yu
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.